As of 2025-05-15, the Intrinsic Value of Rocket Pharmaceuticals Inc (RCKT) is -12.13 USD. This RCKT valuation is based on the model Peter Lynch Fair Value. With the current market price of 6.05 USD, the upside of Rocket Pharmaceuticals Inc is -300.38%.
Based on its market price of 6.05 USD and our intrinsic valuation, Rocket Pharmaceuticals Inc (RCKT) is overvalued by 300.38%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -12.13 - -12.13 | -12.13 | -300.38% |
| P/E | (20.82) - (43.05) | (33.97) | -661.1% |
| DDM - Stable | (26.18) - (569.96) | (298.07) | -5022.7% |
| DDM - Multi | (4.16) - (74.01) | (8.05) | -232.9% |
| Market Cap (mil) | 645.64 |
| Beta | 1.94 |
| Outstanding shares (mil) | 106.63 |
| Enterprise Value (mil) | 503.25 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.44% |
| Cost of Debt | 5.00% |
| WACC | 7.33% |